Hall Brett Matthew 4

What Happened Brett Matthew Hall, Chief Scientific Officer of Immuneering Corp (IMRX), was granted 344,000 derivative shares (reported as an "A"—award/grant) on February 3, 2026. The grant is reported at an acquisition price of $0.00 (no cash paid at grant). This is a compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (filed within the typical two-business-day reporting window).
• Award size: 344,000 derivative shares; reported acquisition price: $0.00.
• Vesting: Vests in equal monthly installments over a four-year period commencing February 1, 2026; fully vested January 1, 2030 (per filing footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Transaction code: A = Award/Grant; no exercise or sale occurred in this filing.

Context This filing documents a standard equity compensation grant to an executive. Such awards are common for aligning executive incentives with shareholder value; they do not represent an immediate purchase or sale of stock. Because these are derivative awards with a multi-year vesting schedule, they do not indicate an immediate change in share count available for sale.